• Global Brain invested in Oyster Therapeutics through TOHO Ventures to support development of targeted protein degraders for neurodegenerative diseases.
• Oyster's lead program is an oral small-molecule degrader designed to clear pathological tau while preserving healthy tau.
• The investor will collaborate with TOHO Holdings to advance Oyster's central nervous system programs toward clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Global Brain Corp published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.